Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds

Drug Development Research

Volumn 68, Issue 4, 2007, Pages 156-163

  Gately, Stephen ^a   West, Robert ^b  

^a RND Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Drug repurposing; Indomethacin; Silicon chemistry

Indexed keywords

ANTIANDROGEN; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA TOPOISOMERASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INDOMETACIN DERIVATIVE; KARENITECIN; MOLECULAR SCAFFOLD; ORGANOSILICON DERIVATIVE; QUADROSILAN; SILPERISONE; SODIUM CHANNEL BLOCKING AGENT; TAC 101; TRIPARANOL; UNCLASSIFIED DRUG; ZIFROSILONE;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; IC 50; PANCREAS CANCER; PATENT; REVIEW;

EID: 35948940015     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20177     Document Type: Review

References (83)

1. Alfthan O, Andersson L, Esposti PL, Fossa SD, Gammelgaard PA, Gjores JE, Isacson S, Rasmussen F, Ruutu M, von Schreeb T, Setterberg G, Strandell P, Strindberg B. 1983. Cisobitan in treatment of prostatic cancer, A prospective controlled multicentre study. Scand J Urol Nephrol 17:37-43.
2. Barnes MJ, Conroy R, Miller DJ, Mills JS, Montana JG, Pooni PK, Showell GA, Walsh LM, Warneck JB. 2007. Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry. Bioorg Med Chem Lett 17:354-357.
3. Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P. 2006. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177:2391-2402.
4. Bertrand G. 2004. Chemistry. The modest undressing of a silicon center. Science 305:783-785.
5. Bikzhanova GA, Toulokhonova IS, Gately S, West R. 2006. Novel silicon-containing drugs derived from the indomethacin scaffold: Synthesis, characterization and evaluation of biological activity. Silicon Chem 3:209-217.
6. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R. 2007. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci USA 104:11927-11932.
7. Burleigh ME, Babaev VR, Patel MB, Crews BC, Remmel RP, Morrow JD, Oates JA, Marnett LJ, Fazio S, Linton MF. 2005a. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem Pharmacol 70:334-342.
8. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. 2005b. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39:443-452.
9. Carley DW. 2005a. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. I Drugs 8:306-309.
10. Carley DW. 2005b. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. I Drugs 8:310-313.
11. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz B, Lai MH, Blanchard KL, Thomas JE. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
12. Chandrasekharan NV, Simmons DL. 2004. The cyclooxygenases. Genome Biol 5:241.
13. Chin FT, Chang YH, Ozkan G, Zou G, Fichter KC, Phillips LR. 1982. Synthesis, hydrolytic reactivity, and anticancer evaluation of N- and O-triorganosilylated compounds as new types of potential prodrugs. J Pharm Sci 71:542-551.
14. Dahan A, Hoffman A. 2007. Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. Drug Metab Dispos 35:321-324.
15. Dannenberg AJ, Subbaramaiah K. 2003. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436.
16. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. 2005. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 11:3009-3016.
17. Draper MP, Martell RL, Levy SB. 1997. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 75:S10-S15.
18. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, D'Amato RJ, Rupnick MA. 2005. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 83:171-181.
19. Eling TE, Baek SJ, Shim M, Lee CH. 2006. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 39:649-655.
20. Esumi H, Lu J, Kurashima Y, Hanaoka T. 2004. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl) ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci 95:685-690.
21. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang HS, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfieldt J. 1988. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31:2235-2246.
22. Farkas S. 2006. Silperisone: a centrally acting muscle relaxant. CNS Drug Rev 12:218-235.
23. Fessenden RJ, Ahlfors C. 1967. The metabolic fate of some silicon-containing carbamates. J Med Chem 10:810-812.
24. Fessenden RJ, Coon MD. 1964. A silicon analog of a sympathomimetic amine. J Med Chem 7:561-562.
25. Fessenden RJ, Coon MD. 1965. Silicon-substituted medicinal agents. Silacarbamates related to meprobamate. J Med Chem 8:604-608.
26. Fessenden RJ, Coon MD. 1966. Silicon-substituted medicinal agents. Phenyl-substituted silacarbamates. J Med Chem 9:262-263.
27. Fessenden RJ, Fessenden JS. 1967. The biological properties of silicon compounds. Adv Drug Res 4:95-132.
28. Fessenden RJ, Hartman RA. 1970. Metabolic fate of phenyltrimethylsilane and phenyldimethylsilane. J Med Chem 13:52-54.
29. Fessenden BJ, Larsen JG, Coon MD, Fessenden JS. 1964. Silicon heterocyclic compounds. 3. Silicon-substituted spirobarbiturates. J Med Chem 7:695-698.
30. Fessenden RJ, Rittenhouse R. 1968. Silicon-substituted medicinal agents. Parasympatholytic activity of 3,3-dimethyl-1-butanol carbamate and 2-trimethylsilyl-1-ethanol carbamate. J Med Chem 11:1070-1071.
31. Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. 2006. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 12:1913-1920.
32. Gaither LA. 2007. Chemogenomics approaches to novel target discovery. Expert Rev Proteomics 4:411-419.
33. Garcia Rodriguez LA, Varas C, Patrono C. 2000. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11:382-387.
34. Garson LR, Kirchner LK. 1971. Organosilicon entities as prophylactic and therapeutic agents. J Pharm Sci 60:1113-1127.
35. Gately S, Li WW. 2004. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy Semin Oncol 31(Suppl 7):2-11.
36. Greene AK, Alwayn IP, Nose V, Flynn E, Sampson D, Zurakowski D, Folkman J, Puder M. 2005. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg 242:140-146.
37. Haaf M, Schmedake TA, West R. 2000. Stable silylenes. Acc Chem Res 33:704-714.
38. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. 2002. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23:107-114.
39. Hawcroft G, Gardner SH, Hull MA. 2003. Activation of peroxisome proliferator-activaled receptor gamma does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells. J Pharmacol Exp Ther 305:632-637.
40. Hermann T. 2007. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 64:1841-1852.
41. Hirata K, Itoh H, Ohsato K. 1994. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Report of two cases. Dis Colon Rectum 37:943-946.
42. Hornsperger JM, Collard JN, Heydt JG, Giacobini E, Funes S, Dow J, Schirlin D. 1994. Trimethylsilylated trifluoromethyl ketones, a novel class of acetylcholinesterase inhibitors: biochemical and pharmacological profile of MDL 73,745. Biochem Soc Trans 22:758-763.
43. Hull MA, Gardner SH, Hawcroft G. 2003. Activity of the nonsteroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev 29:309-320.
44. Inoue J, Aramaki Y. 2007. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen. J Invest Dermatol 127:614-621.
45. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ. 2000a. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 97:925-930.
46. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ. 2000b. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43:2860-2870.
47. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, Hafstrom LO, Kewenter J, Olbe L, Lundell L. 1994. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602-5606.
48. Lundholm K, Daneryd P, Korner U, Hyltander A, Bosaeus I. 2004. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24:505-512.
49. Maca RD, Panje WR. 1982. Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy. Cancer 50:483-489.
50. Matsunaga S, Asano T, Tsutsuda-Asano A, Fukunaga Y. 2006. Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 58:348-353.
51. McCormick KJ, Panje WR. 1986. Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer. Cancer Immunol Immunother 21:226-232.
52. McGeer PL, Rogers J, McGeer EG. 2006. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 9(Suppl):271-276.
53. Mertens WC, Bramwell VH, Gwadry-Sridhar F, Romano W, Banerjee D, Lala PK. 1992. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet 340:397-398.
54. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. 2003. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Williston Park) 17(Suppl 5):15-24.
55. Mills JS, Showell GA. 2004. Exploitation of silicon medicinal chemistry in drug discovery. Expert Opin Investig Drugs 13:1149-1157.
56. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Van Hoff DD. 2002. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314-346.
57. Ohkouchi K, Imoto H, Takakura Y, Hashida M, Sezaki H. 1990. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res 50:1640-1644.
58. Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ. 2007. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol 563:49-60.
59. Panje WR. 1981. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 107:658-663.
60. Pooni PK, Showell GA. 2006. Silicon switches of marketed drugs. Mini Rev Med Chem 6:1169-1177.
61. Rainsford KD. 2007. Anti-inflammatory drugs in the 21st century. Subcell Biochem 42:3-27.
62. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA. 2007. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54:713-720.
63. Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, Jacobs H, Brenckman WD Jr, Lee JS, Petros W, Hong WK, Kurie JM. 2002. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol 20:3522-3532.
64. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611.
65. Rognan D. 2007. Chemogenomic approaches to rational drug design. Br J Pharmacol.
66. Rosenbaum C, Baumhof P, Mazitschek R, Muller O, Giannis A, Waldmann H. 2004. Synthesis and biological evaluation of an indomethacin library reveals a new class of angiogenesis-related kinase inhibitors. Angew Chem Int Ed Engl 43:224-228.
67. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T. 2007. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73:1318-1329.
68. Showell GA, Mills JS. 2003. Chemistry challenges in lead optimization: silicon isosteres in drug discovery. Drug Diseov Today 8:551-556.
69. Showell GA, Barnes MJ, Daiss JO, Mills JS, Montana JG, Tacke R, Warneck JB. 2006. (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorg Med Chem Lett 16:2555-2558.
70. Silverman KJ, Lund DP, Zetter BR, Lainey LL, Shahood JA, Freiman DG, Folkman J, Barger AC. 1988. Angiogenic activity of adipose tissue. Biochem Biophys Res Commun 153:347-352.
71. Simmons DL, Botting HM, Hla T. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437.
72. Suleyman H, Demircan B, Karagoz Y. 2007. Anti-inflammatory and side effects of cyelooxygenase inhibitors. Pharmacol Rep 59:247-258.
73. Tacke R. 1977. [Sila analogs of meflophenhydramine]. Arch Pharm (Weinheim) 310:719-728.
74. Tacke H, Wannagat U. 1977. [N-quaternary derivatives of basic silabenzhydryl ethers]. Arch Pharm (Weinheim) 310:714-719.
75. Tacke H, Wannagat U. 1979. Syntheses and properties of bioactive organo-silicon compounds. Top Curr Chem 84:1-75.
76. Tacke R, Zilch H. 1986. Sila-substitution - a useful strategy for drug design? Endeavour 10:191-197.
77. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. 2004. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23:9247-9258.
78. Timofeevski SL, Prusakiewicz JJ, Ronzer CA, Marnett LJ. 2002. Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis. Biochemistry 41:9654-9662.
79. Waddell WR, Gerner RE. 1980. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 15:85-90.
80. West R. 1984. Isolable Compounds containing a silicon-silicon double bond. Science 225:1109-1114.
81. West R, Fink MJ, Michl J. 1.981. Tetramesityldisilene, a stable compound containing a silicon-silicon double bond. Science 214:1343-1344.
82. Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, Litschig S, Krammer G, Tate GA. 2007. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxf) 46:1126-1132.
83. Yoshinaga K, Teramura M, Iwabe K, Kobayashi S, Masuda M, Motoji T, Mizoguchi H. 2001. Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma. Am J Hematol 66:220-223.